Home > Boards > US Listed > Biotechs > BBC: Best Biotech ETF For Clinical Trials Stocks Holdings (BBC)

Big pharma’s billion-dollar bets

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
stockguard Member Profile
Followed By 20
Posts 1,578
Boards Moderated 0
Alias Born 07/09/05
160x600 placeholder
stockguard   Friday, 06/14/19 04:21:04 PM
Re: None
Post # of 14 
Big pharma’s billion-dollar bets
As patents lapse and funding on R&D is cut, big pharma is spending big money on risky takeovers to find the next blockbuster drug. In this animated film, Due Diligence's Arash Massoudi explains how Bristol-Myers Squibb’s $90B takeover of Celgene has set the stage for more to come in 2019.
As investors have exerted pressure on big pharma to cut back spending on research and development that can result in expensive disappointments, incumbents have been acquiring smaller competitors to replenish drug pipelines.
Nimble start-ups, in contrast, are not weighed down by legacy businesses and can focus on innovation. Many fail but those that succeed, or even show promise by producing just one drug, instantly become takeover targets.
Underpinning these acquisitions is a gamble. Should a big company buy a start-up that has potential but has not proven its worth? Or wait and miss out on a short cut to high returns and new products?


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences